The College of American Pathologists outlines standardized testing and typing methods aimed at reducing diagnostic variability and improving outcomes for patients with this rare but serious disease.
Clinical laboratory leaders facing growing demand for precision diagnostics now have new guidance to support one of pathology’s most complex diagnostic challenges. The College of American Pathologists (CAP) has published an evidence-based guideline designed to standardize laboratory approaches to diagnosing amyloidosis, a rare but life-threatening condition that often goes undetected until advanced stages.
Amyloidosis occurs when abnormal amyloid proteins accumulate in tissues and organs, leading to progressive damage. Because symptoms can mimic other diseases and diagnostic techniques vary widely between laboratories, delays and misclassification have long been a concern. CAP’s new guideline aims to reduce that variability by defining best practices for amyloid detection, fibril protein typing, and specimen evaluation.
The recommendations were developed by a multidisciplinary expert panel that reviewed more than 4,000 peer-reviewed studies. The result is a practical framework intended to help pathologists select the most accurate testing strategies while improving consistency across laboratories.
“This guideline is meant to improve the consistency and accuracy of laboratory diagnoses for systemic amyloidosis,” said Dylan V. Miller, MD, FCAP, guideline co-chair.
Dylan V. Miller, MD, FCAP, guideline co-chair noted, “Clearer standards will support more reliable diagnoses and ultimately better outcomes for patients.” (Photo credit: American Board of Pathology)
Best Practices for Amyloid Detection and Typing
Among the recommendations, the guideline reinforces Congo red staining as the diagnostic standard for detecting amyloid, while noting that fluorescence microscopy may enhance sensitivity in laboratories where it is available. Cytology, including fat pad aspirates, may be appropriate for initial screening due to its minimally invasive nature, but the guideline cautions that such samples are often insufficient for definitive subtyping.
For amyloid protein identification, the panel recommends mass spectrometry as the most accurate and sensitive method, particularly in complex or ambiguous cases. CAP emphasizes that precise protein typing is essential, as treatment options and prognoses vary significantly depending on amyloid subtype.
“Amyloid science is advancing rapidly, with new imaging, typing, and therapies reshaping the field,” said Billie Fyfe-Kirschner, MD, FCAP, guideline co-chair. “For pathologists, staying current is essential to ensure accurate diagnoses and guide patient care.”
Rising Need for Advanced Diagnostics and Long-Term Planning
From a management perspective, the guideline underscores the growing importance of advanced diagnostic capabilities, including access to validated staining methods and mass spectrometry. For lab leaders, this may influence decisions around test menus, referral relationships, and investment in specialized technologies.
CAP plans to reassess the guideline at least every five years, or sooner if major scientific or clinical advances occur. As amyloidosis awareness increases and targeted therapies expand, laboratory accuracy will play an increasingly central role in patient outcomes.
For clinical laboratory leaders and pathologists, the new guideline provides a roadmap for improving diagnostic confidence, standardizing workflows, and aligning laboratory practices with evolving expectations for precision medicine.
—Janette Wider
